Alkem Laboratories Ltd

Alkem Laboratories announced the incorporation of a wholly owned subsidiary in the name of Alkem Pharma Trading FZCO in Dubai, UAE. The subsidiary will undertake export of company's products to African, South East Asian and non-UAE markets.

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5428.5, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.99% on the day, quoting at 24011.35. The Sensex is at 77413.31, up 1.02%. Alkem Laboratories Ltd has slipped around 2.09% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 5.16% in last one month and is currently quoting at 22135.4, up 0.04% on the day. The volume in the stock stood at 34997 shares today, compared to the daily average of 1.27 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 5438.5, up 0.72% on the day. Alkem Laboratories Ltd is up 11.07% in last one year as compared to a 5.18% spurt in NIFTY and a 8.22% spurt in the Nifty Pharma index.The PE of the stock is 29 based on TTM earnings ending December 25.

 Alkem Laboratories announced the launch of A to Z Daily, an everyday multivitamin supplement for adults, for providing holistic nutritional support to the body and mind. A to Z Daily tablets are formulated with a total of 26 essential vitamins, minerals and botanicals to provide balanced nutritional support. The key vitamins and minerals include Vitamin B complex, Vitamin D3, Vitamin C, Zinc, and Iron that help in boosting energy levels, reducing fatigue and improving immunity. The product also contains clinically researched botanicals such as Ashwagandha, Bacopa monnieri (Brahmi), Panax ginseng, and an amino acid L-theanine, which help in managing stress and anxiety, improving sleep quality and supporting the cognitive function. Commenting on the launch, Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, 'Our current lifestyles are placing sustained demands not just on physical health but also on mental well-being. People are increasingly experiencing stress, fatigue, and reduced ability to stay focused. Nutritional supplementation can play a supportive role in addressing these challenges when designed thoughtfully. A to Z Daily brings together essential ingredients to provide a balanced, everyday support for both body and mind. It is positioned not as a quick fix, but as a consistent, long-term approach for people seeking to manage everyday stress while improving overall vitality.'

The certificate is valid for a period of three years from the date of inspection being 09th December, 2025. The inspection was conducted between 5 December 2025 and 9 December 2025. Following the inspection the facility was granted the GMP compliance certificate, subject to three major observations along with a few minor observations noted by the authority. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit rose 2% to Rs 653.53 crore in Q3 FY26, compared with Rs 640.79 crore posted in Q3 FY25. Net sales jumped 10.7% YoY to Rs 3,736.82 crore in the quarter ended 31 December 2025. The scrip rose 0.32% to end at Rs 5,257.75 on the BSE.Powered by Capital Market - Live

The certificate is valid for a period of three years from the date of inspection. According to an exchange filing dated 10 November 2025, an EU GMP inspection by the German health authority was conducted at the company's Baddi manufacturing facility from 4 November 2025 to 10 November 2025. The inspection concluded with no critical or major observations, the company said. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit rose 2% to Rs 653.53 crore in Q3 FY26, compared with Rs 640.79 crore posted in Q3 FY25. Net sales jumped 10.7% YoY to Rs 3,736.82 crore in the quarter ended 31 December 2025. The counter shed 0.17% to Rs 5,342.45 on the BSE. Powered by Capital Market - Live

Alkem Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 5692, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.09% on the day, quoting at 25459.95. The Sensex is at 82146.86, down 0.16%. Alkem Laboratories Ltd has dropped around 1.08% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has dropped around 6.32% in last one month and is currently quoting at 23051.85, up 0.49% on the day. The volume in the stock stood at 50099 shares today, compared to the daily average of 1.38 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 5716, up 1.11% on the day. Alkem Laboratories Ltd is up 23.4% in last one year as compared to a 12.93% spurt in NIFTY and a 14.67% spurt in the Nifty Pharma index.The PE of the stock is 30.35 based on TTM earnings ending December 25.Powered by Capital Market - Live

Alkem Laboratories announced that the United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) on 13 February, 2026 at the manufacturing facility of Enzene Biosciences (Enzene), a subsidiary of the Company in India located at Chakan, Pune. At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved Zero observations related to data integrity - a critical validation of Enzene's quality systems and the reliability of regulatory filings. Enzene is in the process of preparing and submitting its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions. Powered by Capital Market - Live

At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved zero observations related to data integrity ' a critical validation of Enzen's quality systems and the reliability of regulatory filings. Enzene is currently preparing its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions to address the observations. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit rose 2% to Rs 653.53 crore in Q3 FY26, compared with Rs 640.79 crore posted in Q3 FY26. Net sales jumped 10.7% YoY to Rs 3,736.82 crore in the quarter ended 31 December 2025. Shares of Alkem Laboratories added 1.38% to currently trade at Rs 5,475.85 on the BSE. Powered by Capital Market - Live

Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 13 February 2026, inter alia, have recommended the interim dividend of Rs 43 per equity Share (i.e. 2150%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Alkem Laboratories rose 1.63% to Rs 636.02 crore in the quarter ended December 2025 as against Rs 625.82 crore during the previous quarter ended December 2024. Sales rose 10.74% to Rs 3736.82 crore in the quarter ended December 2025 as against Rs 3374.28 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3736.823374.28 11 OPM %22.1622.51 - PBDT929.00816.35 14 PBT833.99731.07 14 NP636.02625.82 2 Powered by Capital Market - Live